Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
127.70
-0.87 (-0.68%)
Jul 9, 2026, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $159.88M in the quarter ending March 31, 2026, with 43.28% growth. This brings the company's revenue in the last twelve months to $569.61M, up 50.19% year-over-year. In the year 2025, Mirum Pharmaceuticals had annual revenue of $521.31M with 54.74% growth.
Revenue (ttm)
$569.61M
Revenue Growth
+50.19%
P/S Ratio
13.67
Revenue / Employee
$1,362,701
Employees
418
Market Cap
7.79B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 521.31M | 184.42M | 54.74% |
| Dec 31, 2024 | 336.89M | 150.51M | 80.76% |
| Dec 31, 2023 | 186.37M | 109.31M | 141.85% |
| Dec 31, 2022 | 77.06M | 57.92M | 302.66% |
| Dec 31, 2021 | 19.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Crinetics Pharmaceuticals | 18.07M |
| Praxis Precision Medicines | 7.46M |
MIRM News
- 2 days ago - Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital - TheFly
- 7 days ago - Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan - TheFly
- 8 days ago - Mirum Pharmaceuticals Slides: Corporate presentation - Filings
- 14 days ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 24 days ago - Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens - TheFly
- 25 days ago - Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study - TheFly
- 25 days ago - Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Business Wire
- 26 days ago - Mirum Pharmaceuticals Slides: Study update presentation - Filings